Monoaminergic agents modulate antidepressant-like effect caused by diphenyl diselenide in rats

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 31, Issue 6, 2007, Pages 1261-1269

  Savegnago, Lucielli ^a   Jesse, Cristiano R ^a   Pinto, Larissa G ^a   Rocha, Joao B T ^a   Nogueira, Cristina W ^a   Zeni, Gilson ^a  

^a Reatividade e Avaliacao Farmacologica e Toxicologica de Organocalcogenios   (Brazil)

Author keywords

Depression; Diphenyl diselenide; Forced swimming test; Monoamines; Selenium

Indexed keywords

8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; ALPHA 1 ADRENERGIC RECEPTOR; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 2 ADRENERGIC RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; DIPHENYL DISELENIDE; DOPAMINE 1 RECEPTOR; DOPAMINE 1 RECEPTOR BLOCKING AGENT; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE 3 RECEPTOR; DOPAMINE 3 RECEPTOR BLOCKING AGENT; FENCLONINE METHYL ESTER; HALOPERIDOL; KETANSERIN; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; ONDANSETRON; PRAZOSIN; SELENIDE; SEROTONIN 1A ANTAGONIST; SEROTONIN 1A RECEPTOR; SEROTONIN 2A ANTAGONIST; SEROTONIN 2A RECEPTOR; SEROTONIN 2C ANTAGONIST; SEROTONIN 2C RECEPTOR; SEROTONIN 3 ANTAGONIST; SEROTONIN 3 RECEPTOR; SULPIRIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; YOHIMBINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DEPRESSION; DRUG ACTIVITY; DRUG DOSE COMPARISON; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; EX VIVO STUDY; FORCED SWIMMING TEST; IMMOBILIZATION; MALE; MONOAMINERGIC SYSTEM; NONHUMAN; OPEN FIELD TEST; RAT;

EID: 84984588435     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2007.05.006     Document Type: Article

References (59)

1. 1A agonists in the treatment of depression. Biol Psychiatry 53 (2003) 193-203
2. Brito V.B., Folmer V., Puntel G.O., Fachinetto R., Soares J.C.M., Zeni G., et al. Diphenyl diselenide and 2,3-dimercaptopropanol increase PTZ-induced chemical seizure and mortality in mice. Brain Res Bull 68 (2006) 414-418
3. Borges L.P., Nogueira C.W., Panatieri R.B., Rocha J.B.T., and Zeni G. Acute liver damage induced by 2-nitropropane in rats: effect of diphenyl diselenide on antioxidant defenses. Chem Biol Interac 160 (2006) 99-107
4. 2A receptors in depression. J Psychiatry Neurosci 29 (2004) 252-265
5. 2c receptors. J Pharmacol Exp Ther 295 (2000) 1120-1126
6. Cryan J.F., Markou A., and Lucki I. Assessing antidepressant activity in rodents: recent developments and future need. TIPS 23 (2002) 238-245
7. D'Aquila P.S., Collu M., Gessa G.L., and Serra G. The role of dopamine in the mechanism of action of antidepressant drugs. Eur J Pharmacol 405 (2000) 365-373
8. Dar A., and Khatoon S. Behavioral and biochemical studies of dichloromethane fraction from the Areca catechu. Nut Pharmacol Biochem Behav 65 (2000) 1-6
9. 2 receptors in depression measured with single photon emission computed tomography. Biol Psychiatry 35 (1994) 128-132
10. Deniker P. The search for new antidepressant and related drugs. In: Tipton K.F., Dostert D., and Benedetti M.S. (Eds). Monoamine oxidase and diseases, prospects for therapy with reversible inhibitors (1984), Academic press, New York, NY 3-8
11. Du L., Bakish D., Lapierre Y.D., Ravindran A.V., and Hrdina P.D. Association of polymorphism of serotonin 2A receptor gene with suicidal ideation in major depressive disorders. Am J Med Genet 96 (2000) 56-60
12. Eckeli A.L., Dach F., and Rodrigues A.L.S. Acute treatments with GMP produce antidepressant-like effects in mice. NeuroReport 11 (2000) 839-843
13. Engstrom G., Alling C., Blennow K., Regnell G., and Traskman-Bendz L. Reduced cerebrospinal HVA concentrations and HVA/5-HIAA ratios in suicide attempters. Monoamine metabolites in 120 suicide attempters and 47 controls. Eur Neuropsychopharmacol 9 (1999) 399-405
14. Elhwuegi A.S. Central monoamines and their role in major depression. Prog Neuro-Psychopharmacol Biol Psychiatry 28 (2004) 435-451
15. 3) receptor. Mol Psychiatry 12 (2003) 994-1007
16. Favero A.M., Weis S.N., Zeni G., Rocha J.B.T., and Nogueira C.W. Diphenyl diselenide changes behavior in female pups. Neurotoxicol Teratol 28 (2006) 697-716
17. Hamner M.B., and Diamond B.I. Plasma dopamine and norepinephrine correlations with psychomotor retardation, anxiety, and depression in nonpsychotic depressed patients: a pilot study. Psychiatry Res 64 (1996) 209-211
18. Harris E.C., and Barraclough B. Excess mortality of mental disorder. Br J Psychiatry 173 (1998) 11-53
19. 1A receptors-G protein interactions in brain following chronic antidepressant administration. Neuropsychopharmacology 26 (2002) 565-573
20. Kaster M.P., Rosa A.O., Santos A.R.S., and Rodrigues A.L.S. Involvement of nitric-oxide-cGMP pathway in the antidepressant-like effects of adenosine in the forced swimming test. Int J Neuropsychopharmacol 8 (2005) 601-606
21. Keller M.B., Lavori P.W., Mueller T.I., Endicott J., Coryell W., Hirschfeld R.M., et al. Time to recovery, chronicity, and levels of psychopathology in major depression. A 5-year prospective follow-up of 431 subjects. Arch Gen Psychiatry 49 (1992) 809-816
22. Krajl M. A rapid microfluorimetric determination of monoamine oxidase. Biochem Pharmacol 14 (1965) 1683-1685
23. Klimek V., Schenck J.E., Han H., Stockmeier C.A., and Ordway GA. Dopaminergic abnormalities in amygdaloid nuclei in major depression: a postmortem study. Biol Psychiatry 52 (2002) 740-748
24. Meotti F.C., Stangherlin E., Zeni G., Nogueira C.W., and Rocha J.B.T. Protective role of aryl and alkyl diselenide on lipid peroxidation. Environ Res 94 (2004) 276-282
25. Meyer J.H., Kruger S., Wilson A.A., Christensen B.K., Goulding V.S., Schaffer A., et al. Lower dopamine transporter binding potential in striatum during depression. NeuroReport 12 (2001) 4121-4125
26. Millan M.J. The role of monoamines in the actions of established and "novel" antidepressant agents: a critical review. Eur J Pharmacol 500 (2004) 371-384
27. Mitani H., Shirayama Y., Yamada T., and Kawahara R. Plasma levels of homovanillic acid, 5-hydroxyindoleacetic acid and cortisol, and serotonin turnover in depressed patients. Prog Neuro-Psychopharmacol Biol Psychiatry 30 (2006) 531-534
28. Musselman D.L., Evans D.L., and Nemeroff C.B. The relationship of depression to cardiovascular disease: epidemiology, biology, and treatment. Arch Gen Psychiatry 55 (1998) 580-592
29. Nemeroff C.B., and Owens M.J. Treatment of mood disorders. Nat Neurosci 5 (2002) 1068-1070 (Suppl.)
30. Nestler E.J., Barrot M., DiLeonem R.J., Eisch A.J., Gold S.J., and Monteggia L.M. Neurobiology of depression. Neuron 34 (2002) 13-25
31. Neumeister A., Willeit M., Praschak-Rieder N., Asenbaum S., Stastny J., Hilger E., et al. Dopamine transporter availability in symptomatic depressed patients with seasonal affective disorder and healthy controls. Psychol Med 31 (2001) 1467-1473
32. Nogueira C.W., Quinhones E.B., Jung E.A.C., Zeni G., and Rocha J.B.T. Anti-inflammatory and antinociceptive activity of diphenyl diselenide. Inflamm Res 52 (2003) 56-63
33. Nogueira C.W., Zeni G., and Rocha J.B.T. Organosellenium and organotellurium compounds: pharmacology and toxicology. Chem Rev 104 (2004) 6255-6286
34. O'Neill M.F., Osborne D.J., Woodhouse S.M., and Conway M.W. Selective imidazoline I2 ligands do not show antidepressant-like activity in the forced swim test in mice. J Psychopharmacol 15 (2001) 18-22
35. Page M.E., Detke M.J., Dalvi A., Kirby L.G., and Lucki I. Serotoninergic mediation of the effects of fluoxetine, but not desipramine, in the rat forced swimming test. Psychopharmacology 147 (1999) 162-167
36. Palucha A., and Pile A. On the role of metabotropic glutamate receptors in the mechanisms of action of antidepressants. Pol J Pharmacol 54 (2002) 581-586
37. Papakostas G.I. Dopaminergic-based pharmacotherapies for depression. Eur Neuropsychopharmacol 16 (2006) 391-402
38. Paulmier C. Selenoorganic functional groups. In: Paulmier C. (Ed). Selenium reagents and intermediates in organic synthesis. 1 ed. (1986), Pergamon Press, Oxford 25-51
39. Peyrot M. Depression: a quiet killer by any name. Diabetes Care 26 (2003) 2952-2953
40. Porsolt R.D., Le Pichon M., and Jalfre M. Depression: a new animal model sensitive to antidepressant treatments. Nature 266 (1977) 730-732
41. Prange Jr. A.J., Wilson I.C., Lynn C.W., Alltop L.B., and Stikeleather RA. l-tryptophan in mania. Contribution to a permissive hypothesis of affective disorders. Arch Gen Psychiatry 30 (1974) 56-62
42. Pratt L., Ford D.E., Crum R.M., Armenian H.K., Gallo J.J., and Eaton W.W. Depression, psychotropic medication, and risk of myocardial infarction. Prospective data from the Baltimore ECA follow-up. Circulation 94 (1996) 3123-3129
43. 3 receptors in the activity of antidepressants in the mouse forced swimming test. Eur J Pharmacol 325 (1997) 129-135
44. Reiche E.M., Nunes S.O., and Morimoto H.K. Stress, depression, the immune system, and cancer. Lancet Oncol 5 (2004) 617-625
45. Rodrigues A.L.S., Da Silva G.L., Mateussi A.S., Fernandes E.S., Miguel O.G., Yunes R.A., et al. Involvement of monoaminergic system in the antidepressant-like effect of the hydroalcoholic extract of Siphocampylus verticillatus. Life Sci 70 (2002) 1347-1358
46. Rossato J.I., Ketzer L.A., Centurião F.B., Silva S.J.N., Ludtke D.S., and Zeni G. Antioxidant properties of new chalcogenides against lipid peroxidation in rat brain. Neurochem Res 3 (2002) 297-303
47. Santos F.W., Zeni G., Rocha J.B.T., Weis S.N., Fachinetto J.M., Favero A.M., et al. Diphenyl diselenide reverses cadmium-induced oxidative damage on mice tissues. Chem Biol Interact 151 (2005) 159-165
48. 11C] WAY-100635: effects of depression and antidepressant treatment. Arch Gen Psychiatry 57 (2000) 174-180
49. Savegnago L., Trevisan M., Alves D., Rocha J.B.T., Nogueira C.W., and Zeni G. Antisecretory and antiulcer effects of diphenyl diselenide. Environ Toxicol Pharmacol 21 (2006) 86-92
50. Savegnago L., Pinto L.G., Jesse C.R., Alves D., Rocha J.B.T., Nogueira C.W., et al. Antinociceptive properties of diphenyl diselenide: evidences for the mechanism of action. Eur J Pharmacol 555 (2007) 129-138
51. 2 binding in depression. Psychol Med 27 (1997) 1247-1256
52. Somerset W., Stout S.C., Miller A.H., and Musselman D. Breast cancer and depression. Oncology (Huntingt.) 18 (2004) 1021-1034 (discussion 1035-1026, 1047-1028)
53. Steffens D.C., Krishnan K.R., and Helms M.J. Are SSRIs better than TCAs? Comparison of SSRIs and TCAs: a meta-analysis. Depress Anxiety 6 (1997) 10-18
54. 2 c receptors and their atypical regulation properties. Life Sci 2 (2003) 2429-2449
55. Walsh R.N., and Cummins R.A. The open-field test: a critical review. Psychol Bull 83 (1976) 482-504
56. Weis S.N., Favero A.M., Stangherlin E.C., Manarin F.G., Rocha J.B.T., Nogueira C.W., et al. Repeated administration of diphenyl diselenide to pregnant rats induces adverse effects on embryonic/fetal development. Reprod Toxicol 23 (2007) 175-181
57. Wong M., and Licinio J. Research and treatment approaches to depression. Nat Rev Neurosci 2 (2001) 343-351
58. Youdim M.B.H., and Weinstock M. Therapeutic applications of selective and non-selective inhibitors of monoamine oxidase A and B that do not cause significant tyramine potentiation. Neurotoxicology 25 (2004) 243-250
59. Zasso F.B., Gonçales C.E.P., Jung E.A.C., Araldi D., Zeni G., Rocha J.B.T., et al. On the mechanisms involved in antinociception induced by diphenyl diselenide. Environ Toxicol Pharmacol 19 (2005) 283-289